Clinical Development

Evotec Signs a License Agreement with Kazia Therapeutics for Clinical Development of EVT801

Shots: Evotec to receive a up front as well as research funding for biomarker development and CMC and is eligible to receive $361.21M as clinical & commercial milestones along with royalties on the net sales of EVT801, which will be shared with Sanofi (partner in the discovery and the development of EVT801) Kazia to get …

Evotec Signs a License Agreement with Kazia Therapeutics for Clinical Development of EVT801 Read More »

FDA rebuff for Keytruda in breast cancer indication

A couple of new developments to report in relation to Merck, known as MSD outside the US and Canada: the first being the rejection by the US FDA of the companyâs application to use its anti-PD-1 therapy, Keytruda, in certain breast cancer patients.

Inside the Pfizer/BioNTech COVID-19 vaccine trial: ‘We knew the world was watching and waiting for results’

The 2020 Pfizer/BioNTech COVID-19 vaccine trial recruited more than 44,000 participants and reached submission for emergency authorization in 248 days: showing unprecedented speed and agility in the context of a global pandemic. So what have been the learnings from the trial â and how could they be applied to vaccine development in the future?

Evidera launches OffTheShelf ™ for historic patient data

Learn more about the detailed patient points and associated physician data available from OffTheShelf. View our infographic. http://bit.ly/evidera-offtheshelf Highlights about OffTheShelf™: Understanding the market trends, market behavior, and competition when developing oncology therapies is critical to optimize market access and product uptake OffTheShelf™ provides access to oncology and hematology patient chart data in 48 hours …

Evidera launches OffTheShelf ™ for historic patient data Read More »

hyperCORE names new CEO

The clinical research site network has tapped 22-year industry veteran Karri Venn, president of research with LMC Manna, to lead the organization.